Recent Updates
Recently added Catalysts
INDV Positive Sentiment Score: 60/100

Indivior Announces Q1 2024 Financial Results Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor...

Key Takeaway: Indivior PLC has announced its financial results for the first quarter ending March 31, 2024. The company remains committed to developing medications for substance use disorders and chronic conditions. In addition, a live webcast presentation will provide further details regarding their performance. Indivior emphasizes its dedication to transforming substance use disorders into recognized chronic diseases with evidence-based treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior reported its Q1 2024 financial results.
  • The company is committed to addressing substance use disorders and serious mental illnesses.
  • Indivior has a pipeline focused on expanding treatment options for various disorders.

Full Press Release Details

SLOUGH, United Kingdom and RICHMOND, Va. , April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV ) today announced its financial results for the period ending March 31, 2024 . The earnings release, investor presentation and webcast are available at www.indivior.com .
There will be a live webcast presentation at 13:00 BST ( 8:00 am EST ) hosted by Mark Crossley , CEO. The details are below.
Webcast link: https://edge.media-server.com/mmc/p/hktzzit4 Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI2351ee9819db40d1a28c31f75cece519
(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA , Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .
SOURCE Indivior PLC

21 %

Frequently Asked Questions

What did Indivior announce on April 25, 2024?

Indivior announced its financial results for the period ending March 31, 2024.

Who will host the live webcast presentation?

Mark Crossley, the CEO of Indivior, will host the live webcast.

What is Indivior focused on developing?

Indivior develops medicines for treating substance use disorders and serious mental illnesses.

In how many countries are Indivior's products available?

Indivior's products are available in 37 countries worldwide.

Last updated: Apr 25, 2024